Although our study, by design, was predisposed to uninformative/contradictory CSF analysis, our results align well with previous findings showing FDG-PET to be more accurate in detecting AD converters than CSF Aβ1–42, p-tau, and t-tau [33, 41–43]. The gene discussed is MAPT; the disease is Alzheimer disease.